# Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

> **NCT03319940** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 269 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Tarlatamab
- **DRUG:** Pembrolizumab
- **DRUG:** CRS Mitigation Strategies

## Key facts

- **NCT ID:** NCT03319940
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-26
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03319940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03319940, "Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03319940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*